Syngeneic Mouse Models

Syngeneic tumor models are used for efficacy testing of immuno-oncologic drugs and the investigation of the effects of conventional anti-cancer drugs on the immune system.

Our panel of cell line-derived syngeneic tumor models (CDX) comprises subcutaneous, subQperior, orthotopic, and metastasis models. Our innovative subQperiorTM tumor models are based on cell implantation into the mammary fat pad of mice and feature reduced tumor ulceration and yield more homogeneous tumor growth and ultimately outstanding statistical evaluation of drug efficacy testing. In addition to standard syngeneic cancer models, Reaction Biology also offers proprietary tissue-based immuno-oncology models, named Mouse-derived Isograft Models (MDI).

  • Science-driven study setup with a focus on reproducible and meaningful results
  • Custom-tailored reports written by PhD level medical writers will be provided for every in vivo study
  • Regular syngenic panel screening of 6 syngeneic tumor models for economic efficacy evaluation of new immuno-oncology drug candidates
  • Comprehensive flow cytometry analysis capacity with 17 marker staining panel

Cell line-derived Syngeneic Mouse Models

Cell Line Tissue Orgin Available Models
4T1 Breast
AB12 Mesothelium
B16-F10 Skin
Clone M3/Cloudman S91 Skin
CT26wt Colon
EMT6 Breast
GL261 Brain subQperior; orthotopic
Hepa1-6 Liver
LL/2 Lung
MC38-CEA# Colon
Pan02 Pancreas subQperior; orthotopic
RENCA Kidney

* subQperior substitute subcutaneous tumor models
# Carcinoembryonic antigen suited for the investigation of tumor-specific T cell response

Options for Tumor Placement